Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer

Akila Viswanathan, Diane Feskanich, Eva S. Schernhammer, Susan E. Hankinson

Research output: Contribution to journalArticle

Abstract

To date, no prospective studies have explored the relationship between the use of aspirin, other nonsteroidal antiinflammatory medications (NSAID), and acetaminophen and endometrial adenocarcinoma. Of the 82,971 women enrolled in a prospective cohort study, 747 developed medical record-confirmed invasive endometrial cancer over a 24-year period. Use of aspirin was ascertained from 1980 to 2004, and for other NSAIDs and acetaminophen, from 1990 to 2004. Cox regression models calculated multivariate relative risks (MV RR), controlling for body mass index (BMI), postmenopausal hormone (PMH) use, and other endometrial cancer risk factors. Currency, duration, and quantity of aspirin were not associated with endometrial cancer risk overall [current use: MV RR, 1.03; 95% confidence interval (CI) 0.83-1.27; >10 years of use: MV RR, 1.01; 95% CI, 0.78-1.30; and cumulative average >7 tablets per week: (MV RR, 1.10; 95% CI, 0.84-1.44)]. However, stratified analyses showed that a lower risk of endometrial cancer among obese (BMI, ≥30 kg/m2) women was seen with current aspirin use (MV RR, 0.66; 95% CI, 0.46-0.95). The greatest risk reduction for current aspirin users was seen in postmenopausal obese women who had never used PMH (MV RR, 0.43; 95% CI, 0.26-0.73). The use of other NSAIDs or acetaminophen was not associated with endometrial cancer. Our data suggest that use of aspirin or other NSAIDs does not play an important role in endometrial cancer risk overall. However, risk was significantly lower for current aspirin users who were obese or who were postmenopausal and had never used PMHs; these subgroup findings require further confirmation.

Original languageEnglish (US)
Pages (from-to)2507-2513
Number of pages7
JournalCancer Research
Volume68
Issue number7
DOIs
StatePublished - Apr 1 2008
Externally publishedYes

Fingerprint

Endometrial Neoplasms
Acetaminophen
Aspirin
Anti-Inflammatory Agents
Confidence Intervals
Non-Steroidal Anti-Inflammatory Agents
Body Mass Index
Hormones
Prospective Studies
Risk Reduction Behavior
Proportional Hazards Models
Tablets
Medical Records
Adenocarcinoma
Cohort Studies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer. / Viswanathan, Akila; Feskanich, Diane; Schernhammer, Eva S.; Hankinson, Susan E.

In: Cancer Research, Vol. 68, No. 7, 01.04.2008, p. 2507-2513.

Research output: Contribution to journalArticle

Viswanathan, Akila ; Feskanich, Diane ; Schernhammer, Eva S. ; Hankinson, Susan E. / Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer. In: Cancer Research. 2008 ; Vol. 68, No. 7. pp. 2507-2513.
@article{03dee2ce92484819b5fa6ef1dc4e76d5,
title = "Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer",
abstract = "To date, no prospective studies have explored the relationship between the use of aspirin, other nonsteroidal antiinflammatory medications (NSAID), and acetaminophen and endometrial adenocarcinoma. Of the 82,971 women enrolled in a prospective cohort study, 747 developed medical record-confirmed invasive endometrial cancer over a 24-year period. Use of aspirin was ascertained from 1980 to 2004, and for other NSAIDs and acetaminophen, from 1990 to 2004. Cox regression models calculated multivariate relative risks (MV RR), controlling for body mass index (BMI), postmenopausal hormone (PMH) use, and other endometrial cancer risk factors. Currency, duration, and quantity of aspirin were not associated with endometrial cancer risk overall [current use: MV RR, 1.03; 95{\%} confidence interval (CI) 0.83-1.27; >10 years of use: MV RR, 1.01; 95{\%} CI, 0.78-1.30; and cumulative average >7 tablets per week: (MV RR, 1.10; 95{\%} CI, 0.84-1.44)]. However, stratified analyses showed that a lower risk of endometrial cancer among obese (BMI, ≥30 kg/m2) women was seen with current aspirin use (MV RR, 0.66; 95{\%} CI, 0.46-0.95). The greatest risk reduction for current aspirin users was seen in postmenopausal obese women who had never used PMH (MV RR, 0.43; 95{\%} CI, 0.26-0.73). The use of other NSAIDs or acetaminophen was not associated with endometrial cancer. Our data suggest that use of aspirin or other NSAIDs does not play an important role in endometrial cancer risk overall. However, risk was significantly lower for current aspirin users who were obese or who were postmenopausal and had never used PMHs; these subgroup findings require further confirmation.",
author = "Akila Viswanathan and Diane Feskanich and Schernhammer, {Eva S.} and Hankinson, {Susan E.}",
year = "2008",
month = "4",
day = "1",
doi = "10.1158/0008-5472.CAN-07-6257",
language = "English (US)",
volume = "68",
pages = "2507--2513",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer

AU - Viswanathan, Akila

AU - Feskanich, Diane

AU - Schernhammer, Eva S.

AU - Hankinson, Susan E.

PY - 2008/4/1

Y1 - 2008/4/1

N2 - To date, no prospective studies have explored the relationship between the use of aspirin, other nonsteroidal antiinflammatory medications (NSAID), and acetaminophen and endometrial adenocarcinoma. Of the 82,971 women enrolled in a prospective cohort study, 747 developed medical record-confirmed invasive endometrial cancer over a 24-year period. Use of aspirin was ascertained from 1980 to 2004, and for other NSAIDs and acetaminophen, from 1990 to 2004. Cox regression models calculated multivariate relative risks (MV RR), controlling for body mass index (BMI), postmenopausal hormone (PMH) use, and other endometrial cancer risk factors. Currency, duration, and quantity of aspirin were not associated with endometrial cancer risk overall [current use: MV RR, 1.03; 95% confidence interval (CI) 0.83-1.27; >10 years of use: MV RR, 1.01; 95% CI, 0.78-1.30; and cumulative average >7 tablets per week: (MV RR, 1.10; 95% CI, 0.84-1.44)]. However, stratified analyses showed that a lower risk of endometrial cancer among obese (BMI, ≥30 kg/m2) women was seen with current aspirin use (MV RR, 0.66; 95% CI, 0.46-0.95). The greatest risk reduction for current aspirin users was seen in postmenopausal obese women who had never used PMH (MV RR, 0.43; 95% CI, 0.26-0.73). The use of other NSAIDs or acetaminophen was not associated with endometrial cancer. Our data suggest that use of aspirin or other NSAIDs does not play an important role in endometrial cancer risk overall. However, risk was significantly lower for current aspirin users who were obese or who were postmenopausal and had never used PMHs; these subgroup findings require further confirmation.

AB - To date, no prospective studies have explored the relationship between the use of aspirin, other nonsteroidal antiinflammatory medications (NSAID), and acetaminophen and endometrial adenocarcinoma. Of the 82,971 women enrolled in a prospective cohort study, 747 developed medical record-confirmed invasive endometrial cancer over a 24-year period. Use of aspirin was ascertained from 1980 to 2004, and for other NSAIDs and acetaminophen, from 1990 to 2004. Cox regression models calculated multivariate relative risks (MV RR), controlling for body mass index (BMI), postmenopausal hormone (PMH) use, and other endometrial cancer risk factors. Currency, duration, and quantity of aspirin were not associated with endometrial cancer risk overall [current use: MV RR, 1.03; 95% confidence interval (CI) 0.83-1.27; >10 years of use: MV RR, 1.01; 95% CI, 0.78-1.30; and cumulative average >7 tablets per week: (MV RR, 1.10; 95% CI, 0.84-1.44)]. However, stratified analyses showed that a lower risk of endometrial cancer among obese (BMI, ≥30 kg/m2) women was seen with current aspirin use (MV RR, 0.66; 95% CI, 0.46-0.95). The greatest risk reduction for current aspirin users was seen in postmenopausal obese women who had never used PMH (MV RR, 0.43; 95% CI, 0.26-0.73). The use of other NSAIDs or acetaminophen was not associated with endometrial cancer. Our data suggest that use of aspirin or other NSAIDs does not play an important role in endometrial cancer risk overall. However, risk was significantly lower for current aspirin users who were obese or who were postmenopausal and had never used PMHs; these subgroup findings require further confirmation.

UR - http://www.scopus.com/inward/record.url?scp=42049102369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42049102369&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-6257

DO - 10.1158/0008-5472.CAN-07-6257

M3 - Article

VL - 68

SP - 2507

EP - 2513

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 7

ER -